ClinicalTrials.gg
Not yet recruitingNCT07083739Updated Jul 24, 2025

A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

A Phase 2 interventional study of TQB3473 Tablets in Primary Immune Thrombocytopenia, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 51 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
4th of 167
320 · median 62
Started
2025
with 26 others
Phase 2
65 of 185
33 open now
Primary completion
2027-09
later than 67 of 91 live
Registered
160th of 185
by date

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 4th largest by planned enrollment of the 167 interventional ones that give a count, is one of 27 that started in 2025, is one of 65 in phase 2, reaches primary completion later than 67 of the 91 other live ones, and was the 160th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

This study is an extension of the TQB3473-III-01 study, aimed at evaluating the safety and efficacy of TQB3473 tablets in adult patients with persistent or chronic ITP who have received at least one ITP standard treatment that is ineffective or has recurred after treatment. This is a single arm, open label, multi cohort, multi center Phase II clinical study.

03

Conditions studied

  • Primary Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1 :

  • Voluntarily participate in this study with signed form (ICF) and demonstrated good compliance.
  • Age ≥18 years (calculated from the date of ICF signing); no gender restrictions; (ECOG) performance status 0-1.
  • Clinically stable condition with WHO bleeding scale score 0-1, and investigator assessment indicates no need for emergency treatment within the next 2 weeks.
  • No increase in the type, dosage, or frequency of concomitant ITP medications compared to the TQB3473-III-01 study regimen.
  • Previous participation in the TQB3473-III-01 study with either: Sustained count \<30×10⁹/L during the 12-week pre-randomization period (\<50×10⁹/L if emergency treatment was received), or completion of 24-week double-blind treatment with investigator-confirmed benefit-risk assessment favoring continued therapy.
  • Adequate major organ function as defined by protocol criteria.
  • For women of : Must agree to use highly effective from screening through 6 months after treatment completion and refrain from oocyte donation for reproductive purposes during this period; must not be breastfeeding with negative serum/urine pregnancy test within 7 days prior to enrollment. For male participants with fertile partners: Must agree to use effective contraception during the study and for 6 months thereafter.

Cohort 2 :

  • Subjects voluntarily participate in this study upon signing the Informed Consent Form (ICF) with demonstrated compliance.
  • Age ≥ 18 years (calculated from signing date of ICF); No gender restrictions; ECOG performance status score 0-1.
  • Confirmed diagnosis of primary ITP >3 months prior to enrollment.
  • Clinically stable condition with WHO bleeding score 0-1, no major bleeding episodes within 4 weeks pre-randomization, and investigators confirm no anticipated need for emergency treatment within 2 weeks.
  • Meeting all platelet criteria: Mean platelet count \<30×10⁹/L (no single value >35×10⁹/L) from ≥2 independent measurements (≥3 days apart) within 7 days pre-enrollment Confirmed platelet count \<30×10⁹/L within 24 hours before enrollment.
  • Documented failure or relapse after ≥1 prior standard ITP therapy.
  • Adequate function of major organs per protocol definitions.
  • Permitted ≤1 concurrent ITP treatment (any class), provided: Stable dose maintained for ≥4 weeks prior to enrollment (≥2 weeks for )
  • For women of childbearing potential: Must agree to use highly effective contraception from screening through 6 months after treatment completion and refrain from oocyte donation for reproductive purposes during this period; must not be breastfeeding with negative serum/urine pregnancy test within 7 days prior to enrollment. For male participants with fertile partners: Must agree to use effective contraception during the study and for 6 months thereafter.

Exclusion criteria

Exclusion Criteria:

  • Cohort 1 :

    1. Due to reasons other than lack of efficacy, receiving TQB3473-III-01 study treatment for less than 12 weeks.
    2. Virus (HBV) DNA or Virus (HCV) RNA detection values exceeding the or decompensated cirrhosis
    3. Previous intracranial hemorrhage or severe bleeding of other important organs (≥ CTC AE grade 3), or symptomatic gastrointestinal bleeding (such as vomiting blood, black stool, etc., except for asymptomatic and asymptomatic "occult blood test positive" and hemorrhoids) within the 6 months before enrollment.
    4. Suffering from major cardiovascular and cerebrovascular diseases.
    5. There are multiple factors that can affect oral medication, such as inability to swallow, chronic diarrhea, and intestinal obstruction.
    6. Those who have received major surgical treatment, significant traumatic injury, or are expected to undergo major elective surgery during the study treatment period within the 4 weeks prior to enrollment
    7. Uncontrolled significant active infections (such as sepsis, pneumonia, or abscess), or severe infections within the 12 weeks prior to enrollment (resulting in hospitalization or requiring antibiotic treatment).
    8. Vaccination was administered within 8 weeks prior to enrollment, or planned during the study period.
    9. Received blood transfusions or blood products within 2 weeks prior to enrollment (excluding IVIg used for emergency treatment).
    10. Take strong inhibitors or inducers (3 weeks for Forsythia suspensa) for 2 weeks or 5 half lives (whichever is longer) before enrollment.
    11. Long term/continuous treatment with drugs that affect function (including but not limited to aspirin, clopidogrel, ticagrelor, NSAIDs, etc.) or anticoagulant therapy is required.
    12. Allergic constitution or history of severe allergies, or known allergies to the components of the drug .
    13. There are clear neurological or mental disorders, or serious psychological or mental abnormalities.
    14. Alcoholic or drug abusers.
    15. According to the researcher's perspective, other severe, acute, or chronic medical or mental illnesses or laboratory abnormalities that may increase the risks associated with participating in the study or interfere with the interpretation of the research results.
    16. It is estimated that the patient's compliance in participating in this clinical study is insufficient.

Cohort 2:

  • There is evidence to suggest the presence of secondary causes of ITP in the subjects, or immune cell depletion of two or more lineages, such as Evans syndrome;
  • Past or current presence of myelofibrosis, myelodysplastic syndrome, aplastic anemia, lymphoproliferative disorders, or other malignant hematological diseases.
  • Have had or currently have malignant tumors within the past 3 years. The following two situations can be included in the group: other malignant tumors treated with a single surgery, achieving continuous 5-year disease-free survival (DFS); Cured cervical carcinoma in situ, non melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basement membrane)].
  • HBV DNA or HCV RNA detection values exceeding the upper limit of normal or decompensated cirrhosis.
  • Previous intracranial hemorrhage or severe (≥ Common Terminology Criteria (CTC) AE grade 3) bleeding of other important organs, or symptomatic gastrointestinal bleeding (such as vomiting blood, black stool, etc., except for asymptomatic and asymptomatic "occult blood test positive" and hemorrhoids) within the 6 months before enrollment.
  • Suffering from major cardiovascular and cerebrovascular diseases.
  • There are multiple factors that can affect oral medication, such as inability to swallow, active gastric ulcers, major gastrointestinal surgeries, chronic diarrhea, and intestinal obstruction.
  • ITP related symptoms and treatment:

    • Received ITP emergency treatment within 2 weeks prior to enrollment;
    • Received platelet transfusion within 2 weeks prior to enrollment;
    • Received immunoglobulin or traditional Chinese medicine treatment within 2 weeks before enrollment;
    • Used rituximab or other anti-Cluster of Differentiation 20 (CD20) drugs within 14 weeks prior to enrollment;
    • Received splenectomy within 12 weeks prior to enrollment;
    • Individuals who have received within the 2 weeks prior to enrollment, or have received thrombopoietin drugs (rhTPO, eltrombopag, hetrombopag, avatrombopag, romiplostim), immunomodulators (azathioprine, cyclosporine A, mycophenolate mofetil), chemotherapy drugs (decitabine, vinblastine), danazol, etc. within the 4 weeks prior to enrollment, except for those who meet the inclusion criteria 8 and are allowed to undergo concomitant treatment.
  • Adverse reactions from previous treatments that have not recovered to ≤ grade 1, as well as non and asymptomatic laboratory abnormalities that have been determined by researchers to pose no safety risks, are excluded.
  • Patients who have received major surgical treatment, significant traumatic injury, or are expected to undergo major elective surgery during the study treatment period within the 4 weeks prior to enrollment (major surgery is defined as surgery at level 3 or above in the National Surgical Classification Catalogue 2022 edition).
  • Vaccination was administered within 8 weeks prior to enrollment, or planned during the study period.
  • Uncontrolled significant active infections (such as sepsis, pneumonia, or abscess), or severe infections within the 12 weeks prior to enrollment (resulting in hospitalization or requiring antibiotic treatment).
  • Received blood transfusions or blood products within 2 weeks prior to enrollment (excluding intravenous immunoglobulin (IVIg) used for emergency treatment).
  • Take strong Cytochrome P450 3A (CYP3A) inhibitors or inducers (3 weeks for Forsythia suspensa) for 2 weeks or 5 half lives (whichever is longer) before enrollment.
  • Participants who have participated in and used other clinical trial drugs within 4 weeks prior to enrollment.
  • Long term/continuous treatment with drugs that affect platelet function (including but not limited to aspirin, clopidogrel, ticagrelor, NSAIDs, etc.) or anticoagulant therapy is required.
  • Allergic constitution or history of severe allergies, or known allergies to the components of the investigational drug excipients.
  • History of important organ transplantation or hematopoietic stem cell/bone marrow transplantation.
  • History of immunodeficiency, including positivity or other congenital immunodeficiency diseases.
  • Individuals with epilepsy who require treatment.
  • There are clear neurological or mental disorders, or serious psychological or mental abnormalities.
  • Alcoholic or drug abusers.
  • According to the researcher's perspective, other severe, acute, or chronic medical or mental illnesses or laboratory abnormalities that may increase the risks associated with participating in the study or interfere with the interpretation of the research results.
  • It is estimated that the patient's compliance in participating in this clinical study is insufficient.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    TQB3473 Tablets

    TQB3473 Tablets 600 mg orally once daily for 24 consecutive weeks.

    Drug: TQB3473 Tablets

Interventions

  • TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.

06

What researchers measure

Primary outcomes

  1. Sustained response rate

    During the last 12 weeks of treatment, at least 2 platelet counts were ≥50×10\^9/L in three protocol-determined visits (excluding rescue treatment).

    Time frame: Weeks 13-24

Secondary outcomes

  1. Response rate at 12 weeks

    ① The percentage of patients with platelet count ≥ 50×10\^9/L at least once within 12 weeks of treatment (excluding emergency treatment). ② The percentage of subjects with a baseline platelet count of\<15 × 10\^9/L who have had at least one platelet count of ≥ 30×10\^9/L within 12 weeks of treatment and an increase of ≥ 20 × 10\^9/L from baseline (excluding emergency treatment);

    Time frame: Within 12 weeks of treatment

  2. Response rate at 24 weeks

    * The percentage of patients with platelet count ≥ 50×10\^9/L at least once within 24 weeks of treatment (excluding emergency treatment). * The percentage of subjects with a baseline platelet count of\<15 × 10\^9/L who have had at least one platelet count of ≥ 30×10\^9/L within 24 weeks of treatment and an increase of ≥ 20 × 10\^9/L from baseline (excluding emergency treatment); ③ The percentage of subjects with platelet counts at least twice the baseline level and ≥30×10\^9/L for at least two consecutive measurements within 24 weeks of treatment (excluding rescue treatment).

    Time frame: Within 24 weeks of treatment

  3. Time to Onset

    The time from the initiation of treatment to the first platelet count ≥50×10\^9/L

    Time frame: Within 24 weeks of treatment

  4. The cumulative duration of platelet count ≥ 50 × 10^9/L within 24 weeks of treatment

    The cumulative duration of platelet count ≥ 50 × 10\^9/L within 24 weeks of treatment.

    Time frame: Within 24 weeks of treatment

  5. The proportion of subjects who receive rescue treatment

    The proportion of subjects who receive rescue treatment aimed to increase platelet counts within 24 weeks of treatment.

    Time frame: Within 24 weeks of treatment

  6. The incidence and severity of bleeding events

    The incidence and severity of bleeding events evaluated according to the World Health Organization (WHO) bleeding scoring criteria within 24 weeks of treatment.

    Time frame: Within 24 weeks of treatment

  7. The change of concomitant therapy

    The proportion of subjects who reduce or discontinue concomitant ITP treatments within 24 weeks of treatment.

    Time frame: Within 24 weeks of treatment

  8. Improvement in Quality of Life Score

    Conduct a comprehensive evaluation of the physical condition of the subjects, and the higher the score, the better the subject's condition.

    Time frame: Within 24 weeks of treatment

  9. The incidence and severity of adverse events (AE) and serious adverse events (SAE), as well as abnormal laboratory test indicators.

    The incidence and severity of adverse events (AE) and serious adverse events (SAE), as well as abnormal laboratory test indicators.

    Time frame: Within 24 weeks of treatment

  10. Area under the curve (0 to Infinity) after initial administration (AUC0-∞)

    Main pharmacokinetic parameters, area under the curve (0 to Infinity) after initial administration (AUC0-∞)

    Time frame: Within 24 weeks of treatment

  11. Maximum plasma concentration (Cmax) after initial administration

    Maximum plasma concentration (Cmax) after initial administration.

    Time frame: Within 24 weeks of treatment

  12. Elimination Half-Life(t1/2)after initial administration

    Elimination Half-Life(t1/2)after initial administration.

    Time frame: Within 24 weeks of treatment

  13. Apparent clearance(CL/F)after initial administration

    Apparent clearance(CL/F)after initial administration.

    Time frame: Within 24 weeks of treatment

  14. Apparent Volume of Distribution (Terminal Phase)(Vz/F)after initial administration

    Apparent Volume of Distribution (Terminal Phase)(Vz/F)after initial administration.

    Time frame: Within 24 weeks of treatment

  15. Terminal elimination Rate Constant (λz) after initial administration

    Terminal elimination Rate Constant (λz) after initial administration.

    Time frame: Within 24 weeks of treatment

  16. Area under the curve (0 to 24 hours) after multiple administration (AUC0-24h)

    Area under the curve (0 to 24 hours) after multiple administration (AUC0-24h).

    Time frame: Within 24 weeks of treatment

  17. Area under the curve (0 to Infinity) after multiple administration (AUC0-∞)

    Area under the curve (0 to Infinity) after multiple administration (AUC0-∞).

    Time frame: Within 24 weeks of treatment

  18. Minimum steady-state concentration (Css-min) after multiple administration

    Minimum steady-state concentration (Css-min) after multiple administration.

    Time frame: Within 24 weeks of treatment

  19. Maximum steady-state concentration (Css-max) after multiple administration

    Maximum steady-state concentration (Css-max) after multiple administration.

    Time frame: Within 24 weeks of treatment

  20. Average Steady-State Concentration (Css-avg) after multiple administration

    Average Steady-State Concentration (Css-avg) after multiple administration.

    Time frame: Within 24 weeks of treatment

  21. Elimination Half-Life (t1/2) after multiple administration

    Elimination Half-Life (t1/2) after multiple administration.

    Time frame: Within 24 weeks of treatment

  22. Apparent Clearance (CL/F) after multiple administration

    Apparent Clearance (CL/F) after multiple administration.

    Time frame: Within 24 weeks of treatment

  23. Apparent volume of distribution (Steady State) after multiple administration (Vss/F)

    Apparent volume of distribution (Steady State) after multiple administration (Vss/F).

    Time frame: Within 24 weeks of treatment

  24. Terminal Elimination Rate Constant (λz) after multiple administration

    Terminal Elimination Rate Constant (λz) after multiple administration.

    Time frame: Within 24 weeks of treatment

  25. Accumulation ratio constant (Rac) after multiple administration

    Accumulation ratio constant (Rac) after multiple administration.

    Time frame: Within 24 weeks of treatment

  26. Degree of fluctuation (DF) after multiple administration

    Degree of fluctuation (DF) after multiple administration.

    Time frame: Within 24 weeks of treatment

07

Study locations

51 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Sep 2027, 25 months later.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartEst.
Aug 2025
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2028
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07083739
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Aug 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jul 24, 2025

Study contacts

Hu Zhou, Doctor
Contact
papertigerhu@163.com
13939068863

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB3473

Start the discussion